Warning: The NCBI web site requires JavaScript to function. more...
The role of animal models in advancing amyloid-beta immunotherapy to the clinic.
Games D, Seubert P.
Alzheimers Res Ther. 2010 Jul 29;2(4):22.
Related citations
Amyloid-beta immunotherapy for Alzheimer's disease.
Fu HJ, Liu B, Frost JL, Lemere CA.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. Review.
Alternative Abeta immunotherapy approaches for Alzheimer's disease.
Town T.
CNS Neurol Disord Drug Targets. 2009 Apr;8(2):114-27. Review.
Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
Lemere CA.
Prog Brain Res. 2009;175:83-93. Review.
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
Cribbs DH.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):207-16. Review.
Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid.
Frisardi V, Solfrizzi V, Imbimbo PB, Capurso C, D'Introno A, Colacicco AM, Vendemiale G, Seripa D, Pilotto A, Capurso A, Panza F.
Curr Alzheimer Res. 2010 Feb;7(1):40-55. Review.
Current progress in beta-amyloid immunotherapy.
Schenk D, Hagen M, Seubert P.
Curr Opin Immunol. 2004 Oct;16(5):599-606. Review.
Immunological approaches as therapy for Alzheimer's disease.
Solomon B.
Expert Opin Biol Ther. 2002 Dec;2(8):907-17. Review.
Can Alzheimer disease be prevented by amyloid-beta immunotherapy?
Lemere CA, Masliah E.
Nat Rev Neurol. 2010 Feb;6(2):108-19. Review. Erratum in: Nat Rev Neurol. 2010 Apr;6(4):183. Nat Rev Neurol. 2010 Jun;6(6):296.
Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease.
Golde TE, Dickson D, Hutton M.
Curr Alzheimer Res. 2006 Dec;3(5):421-30. Review.
Immunotherapy for Alzheimer's disease.
Solomon B, Frenkel D.
Neuropharmacology. 2010 Sep-Oct;59(4-5):303-9. Epub 2010 Apr 11. Review.
Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.
Nitsch RM, Hock C.
Neurotherapeutics. 2008 Jul;5(3):415-20. Review.
Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
Panza F, Solfrizzi V, Frisardi V, Imbimbo BP, Capurso C, D'Introno A, Colacicco AM, Seripa D, Vendemiale G, Capurso A, Pilotto A.
Aging Clin Exp Res. 2009 Dec;21(6):386-406. Review.
Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
Menéndez-González M, Pérez-Piñera P, Martínez-Rivera M, Muñiz AL, Vega JA.
Curr Pharm Des. 2011;17(5):508-20. Review.
Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
Tarawneh R, Holtzman DM.
CNS Neurol Disord Drug Targets. 2009 Apr;8(2):144-59. Review.
Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
Wisniewski T, Boutajangout A.
Brain Struct Funct. 2010 Mar;214(2-3):201-18. Epub 2009 Dec 10. Review.
Alzheimer's disease and immunotherapy.
Curr Alzheimer Res. 2004 Aug;1(3):149-63. Review.
Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.
Creed MC, Milgram NW.
Age (Dordr). 2010 Sep;32(3):365-84. Epub 2010 Apr 20. Review.
Vaccine development for Alzheimer's disease.
Dasilva KA, Aubert I, McLaurin J.
Curr Pharm Des. 2006;12(33):4283-93. Review.
[Recent progress in the development of disease-modifying therapies for Alzheimer's disease].
Abe K.
Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Feb;30(1):1-8. Japanese.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on